Personalized Approaches to Sustained Biologic Remission in Crohn’s Disease: Mucosal Healing in Crohn’s Disease
Personalized Approaches to Sustained Biologic Remission in Crohn’s Disease:
Introduction: Mucosal Healing in Crohn’s Disease (CD)
Case 1: Assessing mucosa in mild to moderate CD patients
Case 2: Preventing relapse and maintaining mucosal health in a CD patient who recently underwent an ileocecectomy
Case 3: Assessment of mucosal healing in a CD patient with perianal disease as assessed by serial MRI
Case 4: Mucosal healing in a patient with severe CD being treated with biologic therapy
Crohn’s disease is a chronic, inflammatory disorder that can become disabling over time. Because it is a lifelong disease, maintaining symptomatic control and attaining remission are critical to minimizing short- and long-term complications and improving outcomes and quality of life for patients. To help improve outcomes for patients with Crohn’s disease, the concept of mucosal healing (also referred to as sustained biologic remission) has been proposed as a therapeutic end point to gauge if treatment has reduced the intestinal mucosal damage that frequently accompanies Crohn’s disease. This video will provide guidance on the appropriate use of mucosal healing in clinical settings. It begins with an overview of the use of mucosal healing in Crohn’s disease followed by a discussion of four case studies.
This activity is supported by independent educational grants from AbbVie, Prometheus, and UCB, Inc.
Joint Provider: FACTORx, and MedEd Consulting
This activity has been designed to meet the educational needs of gastroenterologists and other health care professionals involved in the care of patients with CD.
At the conclusion of this activity, participants should be able to:
- Discuss the clinical benefits of mucosal healing in patients with CD;
- Design an effective treatment plan that maximizes the occurrence of mucosal healing in patients with CD;
- Evaluate the clinical utility of colonoscopy, non-invasive imaging techniques, and biomarkers for the assessment of mucosal healing in patients with CD.
The Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
The University of Chicago Medicine
Professor of Medicine and Adjunct Professor of Surgery
Chief, Division of Gastroenterology
Director, UCSD IBD Center
University of California, San Diego and UC San Diego Health System
La Jolla, CA
Professor of Medicine
Raymond and Ruth Perelman School of Medicine of the
University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of The University of Chicago Pritzker School of Medicine, FACTORx, and MedEd Consulting. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.